A major challenge in the fight against filovirus infections is the fact that the nature of epidemics cannot be predicted. Beside the Zaire strain of Ebolavirus other ebolaviruses such as Sudan virus, Bundibugyo virus as well as the more distant…
In 2014, the alarm for the Zaire Ebola virus was sounded around the world—but there are other deadly ebolaviruses that cause identical symptoms, and they have even fewer treatment options. In a study publishing May 5 in Cell Reports, researchers…
Integrated BioTherapeutics, Inc. (IBT), a leader in infectious disease and filovirus research, today announced the discovery of novel Pan-Ebola and Pan-Filovirus monoclonal antibodies (mAbs). IBT scientists presented the new mAbs at the 7th International Symposium on Filoviruses held in Washington,…
MEDFORD, N.Y., Jan. 12, 2015 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, today announced its progress in the development of DPP® Ebola and DPP® Febrile Illness Assays. On October 27,…
Integrated BioTherapeutics Partners With Chembio to Develop Point-of-Care Diagnostic Tests for Ebola and Febrile Illness Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, today announced that it has entered into an exclusive agreement with Integrated BioTherapeutics, Inc. (IBT), a biotechnology…
A Novel Paradigm for Fighting Staphylococcal Infections and Their Complications The pathogenicity of Staphylococcus aureus (S. aureus) is dependent on a wide range of virulence factors including cell surface proteins, polysaccharides, and secreted toxins. Surface antigens mediate the attachment of…
Integrated Biotherapeutics (IBT) and its partners have published what is believed to be a novel conservation strategy in the prestigious journal Proceedings of the National Academies of Sciences (PNAS), wherein captive chimpanzees are vaccinated against Ebola virus to establish vaccine…
IBT and Stanford Awarded STTR for HCV Therapeutic Antibodies Integrated BioTherapeutics (IBT) and Stanford University have been jointly awarded a $300,000 Small Business Technology Transfer (STTR) grant from the National Institute of Allergy and Infectious Diseases of the National Institutes…
Integrated BioTherapeutics (IBT) announces the initiation of a Phase 1 clinical trial testing the safety and immunogenicity of its staphylococcal enterotoxin B vaccine "STEBVAX" in healthy adults. This trial, marking the first time a superantigen vaccine has been administered to…
SBIR Award: Integrated BioTherapeutics to Create Therapeutic Multi-Specific Antibodies Using Technology from Zyngenia Integrated Biotherapeutics (IBT) has been awarded a Phase I Small Business Innovative Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID), a division…